Investigational drug · Phase 3
Ripasudil
Also called: K-321
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fuchs Endothelial Corneal Dystrophy.
Phase 3Last checked: Nov 19, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
12
Any phase or sponsor naming "Ripasudil"
First trial start
2023
Mar 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ripasudil", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fuchs Endothelial Corneal Dystrophy
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Ripasudil" as an intervention, largest first.
- A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryPivotal-lookingCompleted
Kowa Research Institute, Inc.Industry
NCT05528172 · 330 participants · Start Aug 4, 2022 · Primary completion Jun 22, 2023
Drug: Ripasudil; Placebo · For: Corneal Edema After Cataract Surgery
Sites: Phoenix, Arizona; Scottsdale, Arizona; Hemet, California · 45 sites in all
- Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT04620135 · 245 participants · Start Nov 30, 2020 · Primary completion Jul 9, 2021
Drug: Netarsudil ophthalmic solution 0.02%; Ripasudil hydrochloride hydrate ophthalmic solution 0.4% · For: Primary Open Angle Glaucoma; Ocular Hypertension
Sites: Setagaya-Ku, Japan
- Descemet Endothelial Thickness Comparison Trial IPivotal-lookingActive, not recruiting
Stanford UniversityAcademic, hospital or other
NCT05289661 · 160 participants · Start Jul 15, 2022 · Primary completion Nov 30, 2026
Drug: Topical Ripasudil; Topical Placebo · For: Fuchs
Sites: Palo Alto, California; Sacramento, California; Palm Beach Gardens, Florida · 7 sites in all
- The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract SurgeryPivotal-lookingRecruiting
Singapore Eye Research InstituteAcademic, hospital or other
NCT06048380 · 120 participants (planned) · Start Mar 1, 2025 · Primary completion Jul 2025
Drug: Ripasudil · For: Fuchs' Endothelial Dystrophy; Cataract
Sites: Singapore, Singapore
- A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)Pivotal-lookingCompleted
Kowa Research Institute, Inc.Industry
NCT05826353 · 110 participants · Start May 11, 2023 · Primary completion Jan 17, 2025
Drug: Ripasudil; Placebo · For: Fuchs Endothelial Corneal Dystrophy
Sites: Los Angeles, California; Palo Alto, California; Sacramento, California · 43 sites in all
- A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)Pivotal-lookingCompleted
Kowa Research Institute, Inc.Industry
NCT05795699 · 107 participants · Start Mar 30, 2023 · Primary completion May 22, 2025
Drug: Ripasudil; Placebo · For: Fuchs Endothelial Corneal Dystrophy
Sites: Los Angeles, California; Palo Alto, California; Sacramento, California · 50 sites in all
- Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' DystrophyStatus unknown
Michael D. Straiko, MDAcademic, hospital or other
NCT03813056 · 72 participants (planned) · Start Mar 25, 2019 · Primary completion Feb 1, 2025
Drug: Glanatec; Optive, Ophthalmic Solution · For: Fuchs Endothelial Dystrophy
Sites: Portland, Oregon
- Descemet Endothelial Thickness Comparison Trial IIPivotal-lookingActive, not recruiting
Stanford UniversityAcademic, hospital or other
NCT05275972 · 60 participants · Start Jan 23, 2023 · Primary completion Oct 30, 2027
Drug: Ripasudil; Placebo · For: Fuchs; Fuchs Dystrophy; Fuchs' Endothelial Dystrophy
Sites: Palo Alto, California; Sacramento, California; Palm Beach Gardens, Florida · 8 sites in all
Marian Macsai, MDAcademic, hospital or other
NCT03249337 · 30 participants (planned) · Start Dec 6, 2017 · Primary completion Dec 2021
Drug: Ripasudil hydrochloride hydrate 0.4% ophthalmic solution · For: Fuchs' Endothelial Dystrophy
Sites: Glenview, Illinois
Kyushu UniversityAcademic, hospital or other
NCT04621136 · 24 participants · Start Nov 1, 2020 · Primary completion Nov 30, 2022
Drug: Ripasudil ophthalmic solution 0.4% · For: Retinopathy of Prematurity
Sites: Kitakyushu, Japan; Ube, Japan; Fukuoka, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Rho Kinase inhibitors in ophthalmology: The current status and comparative evaluation of Netarsudil and Ripasudil.
Singh MD · Indian J Ophthalmol 2026
- Descemet Stripping Only in Fuchs Endothelial Corneal Dystrophy: Results of a Randomized Clinical Trial of Topical Ripasudil and Directions for Future Innovation.
Colby K, Kruse FE, Kinoshita S · Am J Ophthalmol 2026
- Smart lipid-based nanocarrier system for the topical delivery of ocular therapeutics bio-interfacing, physicochemical diversity, and routing barriers.
Singh M, Singh S, Sharma P, et al. · Eur J Pharm Sci 2026
- Asymmetric Bilateral Axenfeld-Rieger Anomaly Misdiagnosed as Unilateral Iridocorneal Endothelial Syndrome.
Satish N, Sethi S · Cureus 2026
- Targeting RhoA/ROCK Signaling to Modulate Extracellular Matrix Remodeling in Corneal Endothelial Dystrophies.
Schlötzer-Schrehardt U, Zenkel M, Pulasani S, et al. · Invest Ophthalmol Vis Sci 2026
- Efficient electrochemical defluorination of fluorinated drugs in aqueous medium with product monitoring by ion selective electrode/mass spectrometry methods.
Dushna O, Gawor A, Piczek L, et al. · Talanta 2026
Also in development for Fuchs Endothelial Corneal Dystrophy
- DT-168Phase 21 trial
Design Therapeutics, Inc. · Fuchs Endothelial Corneal Dystrophy, Fuchs
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.